UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 793

Sortiert nach

2. Prospects and Challenges for Cancer Genomic Medicine

Nihon Naika Gakkai Zasshi, 2021/09/10, Vol.110(9), pp.1885-1889

Nishio, Kazuto

2021

Link zum Volltext

Verfügbarkeit prüfen

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Clinical cancer research, 2018-06, Vol.24 (11), p.2653-2664

2018

Link zum Volltext

Verfügbarkeit prüfen

LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both

Journal of clinical oncology, 2013-09, Vol.31 (27), p.3335-3341

2013

Link zum Volltext

Verfügbarkeit prüfen

Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer

Molecular cancer therapeutics, 2017-02, Vol.16 (2), p.357-364

2017

Link zum Volltext

Verfügbarkeit prüfen

An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC

Oncogene, 2019-02, Vol.38 (9), p.1398-1409

2019

Link zum Volltext

Verfügbarkeit prüfen

Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer

Cancer science, 2019-01, Vol.110 (1), p.52-60

2019

Link zum Volltext

Verfügbarkeit prüfen

Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor

Cancer science, 2007-08, Vol.98 (8), p.1275-1280

2007

Link zum Volltext

Verfügbarkeit prüfen

Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts

British journal of cancer, 2021-03, Vol.124 (5), p.914-924

2021

Link zum Volltext

Verfügbarkeit prüfen

Exploration of resistance mechanisms for epidermal growth factor receptor‐tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next‐generation sequencing

Cancer science, 2018-12, Vol.109 (12), p.3921-3933

2018

Link zum Volltext

Verfügbarkeit prüfen

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G

Cancer science, 2016-12, Vol.107 (12), p.1843-1850

2016

Link zum Volltext

Verfügbarkeit prüfen

The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine

Pathology international, 2021-11, Vol.71 (11), p.725-740

2021

Link zum Volltext

Verfügbarkeit prüfen

Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor-Induced Apoptosis in EML4-ALK-Positive Lung Cancer

Clinical cancer research, 2011-04, Vol.17 (8), p.2140-2148

2011

Link zum Volltext

Verfügbarkeit prüfen

Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor

Cancer science, 2013-09, Vol.104 (9), p.1198-1204

2013

Link zum Volltext

Verfügbarkeit prüfen

HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer

Clinical cancer research, 2022-01, Vol.28 (2), p.390-403

2022

Link zum Volltext

Verfügbarkeit prüfen

Multiplex gene‐panel testing for lung cancer patients

Pathology international, 2020-12, Vol.70 (12), p.921-931

2020

Link zum Volltext

Verfügbarkeit prüfen

Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer

Clinical cancer research, 2006-07, Vol.12 (13), p.3915-3921

2006

Link zum Volltext

Verfügbarkeit prüfen

Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer

PloS one, 2014-07, Vol.9 (7), p.e102436

2014

Link zum Volltext

Verfügbarkeit prüfen

Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA

Cancer science, 2021-09, Vol.112 (9), p.3911-3917

2021

Link zum Volltext

Verfügbarkeit prüfen

Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib

Scientific reports, 2020-01, Vol.10 (1), p.691-691, Article 691

2020

Link zum Volltext

Verfügbarkeit prüfen

Performance of Oncomine Fusion Transcript kit for formalin‐fixed, paraffin‐embedded lung cancer specimens

Cancer science, 2019-06, Vol.110 (6), p.2044-2049

2019

Link zum Volltext

Verfügbarkeit prüfen

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?

Cancer science, 2016-08, Vol.107 (8), p.1134-1140

2016

Link zum Volltext

Verfügbarkeit prüfen

Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing

Scientific reports, 2019-07, Vol.9 (1), p.10426-8, Article 10426

2019

Link zum Volltext

Verfügbarkeit prüfen

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK―Positive Non―Small Cell Lung Cancer

Clinical cancer research, 2012-11, Vol.18 (22), p.6219-6226

2012

Link zum Volltext

Verfügbarkeit prüfen

Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients

Cancer science, 2019-10, Vol.110 (10), p.3350-3357

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 793

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(688)
Mit Volltextzugriff
(757)

Publikationsform

Sprache

Englisch
(750)
Japanisch
(221)
Koreanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancer Research
(142)
Cancer Science
(68)
International Journal Of Cancer
(35)
Annals Of Oncology
(32)
Journal Of Clinical Oncology
(32)
Japanese Journal Of Cancer Research
(28)
Journal Of Thoracic Oncology
(22)
Lung Cancer
(20)
Cancer Chemotherapy And Pharmacology
(18)
Clinical Cancer Research
(18)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

2. Prospects and Challenges for Cancer Genomic Medicine

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both

Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer

An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC

Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer

Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor

Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts

Exploration of resistance mechanisms for epidermal growth factor receptor‐tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next‐generation sequencing

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G

The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine

Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor-Induced Apoptosis in EML4-ALK-Positive Lung Cancer

Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor

HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer

Multiplex gene‐panel testing for lung cancer patients

Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer

Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer

Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA

Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Performance of Oncomine Fusion Transcript kit for formalin‐fixed, paraffin‐embedded lung cancer specimens

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?

Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK―Positive Non―Small Cell Lung Cancer

Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients

Suchergebnisse filtern